---
title: "Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285763802.md"
description: "Nexalin Technology, Inc. reported a revenue of $14.95K for Q1 2026, down 63.5% from $41.02K a year prior, with a net loss of $2.1M and diluted EPS of ($0.11). The decline in revenue was attributed to lower international equipment sales, although a shift towards higher-margin licensing fees improved gross margins. The company initiated a pivotal insomnia trial and reported increased operating expenses, raising concerns about its financial viability."
datetime: "2026-05-08T18:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285763802.md)
  - [en](https://longbridge.com/en/news/285763802.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285763802.md)
---

# Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary

Nexalin Technology, Inc. reported first-quarter 2026 results with revenue down to $14.95K from $41.02K a year earlier and a net loss of ($2.1M), or diluted EPS of ($0.11).

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$14.95K

$41.02K

(63.5%)

Net income²

($2.1M)

($1.99M)

(5.5%)

Diluted EPS³

($0.11)

($0.15)

26.7%

_¹ Reported as “Revenues, net (includes related party of $ 0 and $ 3,583 for the three months ended March 31, 2026 and March 31, 2025, respectively)”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders - Basic and Diluted”._

**Business Highlights**

-   Revenue trend: Revenues declined about 64% year over year to approximately $15K in Q1 2026, driven by lower international equipment sales.
-   Channel shift: The company reported a shift in mix toward higher‑margin licensing fees versus device and equipment sales, which improved gross margin dynamics.
-   Product and regulatory milestones: FDA accepted a Q‑Submission for Gen‑2 SYNC, and the Gen‑3 HALO pivotal insomnia trial was initiated with a UK CRO statement of work.
-   Operating outlook: Operating expenses rose modestly due to higher professional fees and increased headcount; cash burn to fund trials and development continues, creating material doubt about going concern.

Original SEC Filing: Nexalin Technology, Inc. \[ NXL \] - 10-Q - May. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 | CVSI Stock News](https://longbridge.com/en/news/286163474.md)
- [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md)
- [AleAnna, Inc. Reports First Quarter 2026 Results | ANNA Stock News](https://longbridge.com/en/news/286463118.md)
- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)
- [Comex Silver Settles 0.11% Lower at $77.073 — Data Talk](https://longbridge.com/en/news/286805320.md)